Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma

HIGHLIGHTS

• What: The authors compared the efficacy and safety of NICT and NCT after a median follow-up of 36.0 months.
• Who: Huilai Lv from the Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, NO [12, ]JianKang Road, Shijiazhuang, Hebei, China have published the research work: Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma, in the Journal: (JOURNAL)
• How: This trial preliminarily shows that NICT improves pathological and survival outcomes over NCT for resectable locally advanced ESCC with acceptable and manageable safety.

 

If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.